Go forward and treat with confidence

Endometrial cancer

Myriad Oncology can help you make the decisions that matter most by providing crucial information about your patients’ endometrial cancer. Administering an accurate genetic test will provide you both peace of mind because knowing if their endometrial cancer was caused by a genetic mutation will help guide treatment and risk management decisions, as well as provide information on potential familial risk.

Patient care begins with knowledge, and your patients deserve accurate and actionable hereditary cancer test results that you trust.

Myriad Oncology's Tests for Endometrial Cancer and What Answers They Provide:​

HEREDITARY CANCER TESTING​

myRisk genetic testing

The Myriad myRisk® test is a 35-gene cancer panel that will provide your patients with endometrial cancer with information on:

  • Whether or not their case of endometrial cancer is hereditary (or caused by a genetic mutation) – Approximately 1 in 4 newly diagnosed patients with endometrial cancer are at risk for Lynch syndrome and appropriate for genetic evaluation.1
  • Their risk of developing additional cancers – In a study of women with Lynch syndrome, women face up to 20% chance of developing a second primary cancer within 10 years after Lynch syndrome related endometrial cancer and up to 48% after 20 years.2
  • Potential surgical considerations and treatment eligibility – Knowing a patient’s Lynch syndrome status may change surgical considerations for women, potentially including a total abdominal hysterectomy with a bilateral salpingo-oophorectomy (TAH/BSO).3
  • Potential hereditary cancer risk for family members – Knowing mutation status provides the opportunity for family members to take proactive screening and/or preventative measures if appropriate.

By incorporating leading medical society guidelines into the results through our myRisk Medical Management Tool, myRisk can provide comprehensive information about your patient’s unique cancer. Using industry leading accuracy, unmatched turnaround time, and a lifetime commitment to patients, myRisk should be a part of endometrial cancer workups.

explore other cancer types

Click the cancer type below to see what test(s) and answers Myriad Oncology offers for that cancer type.

References
  1. Hampel H, et al. Screening for Lynch syndrome (hereditary non-polyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006 Aug 1;66(15):7810-7817.
  2. Win AK, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013 Feb 20; 105(4):274-279.
  3. Referenced with permission from the NCCN: Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020. ©National Comprehensive Cancer Network, Inc. 2020.